ArticleSmall (Weinheim an der Bergstrasse, Germany)2013
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy.
Article in Small (Weinheim an der Bergstrasse, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- A Comprehensive Analysis of Natural Bioactive Molecules for the Treatment and Control of Glioblastoma Multiforme (GBM) Targeting Underlying Molecular Mechanism.Chemistry & biodiversity · 2026Review
- Nanoparticle-Mediated Transcytosis in Tumor Drug Delivery: Mechanisms, Categories, and Novel Applications.Current drug delivery · 2026Review
- Glioblastoma: A Multidisciplinary Approach to Its Pathophysiology, Treatment, and Innovative Therapeutic Strategies.Biomedicines · 2025Review
- Targeting the glioblastoma resection margin with locoregional nanotechnologies.Nature reviews. Clinical oncology · 2025Review
- Neural Stem Cells as Carriers of Nucleoside-Conjugated Nanogels: A New Approach toward Cell-Mediated Delivery.ACS applied materials & interfaces · 2023Article
- Photothermal treatment of glioblastoma cells based on plasmonic nanoparticles.Lasers in medical science · 2023Article
- Reactive oxidative species (ROS)-based nanomedicine for BBB crossing and glioma treatment: current status and future directions.Frontiers in immunology · 2023Review
- Neural stem cell‑derived exosomes transfer miR‑124‑3p into cells to inhibit glioma growth by targeting FLOT2.International journal of oncology · 2022Article
- Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma.Journal of nanobiotechnology · 2022Review
- ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survival.Science advances · 2021Article
- Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2021Article
- Role and mechanism of neural stem cells of the subventricular zone in glioblastoma.World journal of stem cells · 2021Review
- Stem cells for the treatment of glioblastoma: a 20-year perspective.CNS oncology · 2021Review
- Allogeneic human neural stem cells for improved therapeutic delivery to peritoneal ovarian cancer.Stem cell research & therapy · 2021Article
- Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges.International journal of molecular sciences · 2021Review
- Lipid-Based Nanocarriers for The Treatment of Glioblastoma.Advanced nanobiomed research · 2021Article
- Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.Frontiers in bioengineering and biotechnology · 2020Review
- Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy.The Journal of pharmacology and experimental therapeutics · 2019Review
- Seeing Better and Going Deeper in Cancer Nanotheranostics.International journal of molecular sciences · 2019Review
- Silica Coated Paclitaxel Nanocrystals Enable Neural Stem Cell Loading For Treatment of Ovarian Cancer.Bioconjugate chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
A 3-step glioblastoma-tropic delivery and therapy method using nanoparticle programmed self-destructive neural stem cells (NSCs) is demonstrated in vivo: 1) FDA-approved NSCs for clinical trials are loaded with pH-sensitive MSN-Dox; 2) the nanoparticle conjugates provide a delayed drug-releasing mechanism and allow for NSC migration towards a distant tumor site; 3) NSCs eventually undergo cell death and release impregnated MSN-Dox, which subsequently induces toxicity towards surrounding glioma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.